Evidence map›Paper›PMID 24409060›Full record

ArticleWorld journal of gastroenterology2013

Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.

Jan Harder, Michael J Müller, Matthias Fuchs, Vera Gumpp, Annette Schmitt-Graeff, Richard Fischer, Melanie Frank, Oliver Opitz, Jens Hasskarl

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jan HarderJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Michael J MüllerJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Matthias FuchsJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Vera GumppJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Annette Schmitt-GraeffJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Richard FischerJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Melanie FrankJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Oliver OpitzJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Jens HasskarlJan Harder, Department of Gastroenterology, Hematology and Oncology, Hegau-Bodensee-Hochrhein Kliniken, 78221 Singen, Germany.
Iomedico (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the expression and clinical relevance of inhibitor of differentiation (ID) proteins in biliary tract cancer.

methodsID protein expression was analyzed in 129 samples from patients with advanced biliary tract cancer (BTC) (45 extrahepatic, 50 intrahepatic, and 34 gallbladder cancers), compared to normal controls and correlated with clinical an pathological parameters.

resultsID1-3 proteins are frequently overexpressed in all BTC subtypes analyzed. No correlation between increased ID protein expression and tumor grading, tumor subtype or treatment response was detected. Survival was influenced primary tumor localization (extrahepatic vs intrahepatic and gall bladder cancer, OS 1.5 years vs 0.9 years vs 0.7 years, P = 0.002), by stage at diagnosis (OS 2.7 years in stage I vs 0.6 years in stage IV, P < 0.001), resection status and response to systemic chemotherapy. In a multivariate model, ID protein expression did not correlate with clinical prognosis. Nevertheless, there was a trend of shorter OS in patients with loss of cytoplasmic ID4 protein expression (P = 0.076).

conclusionID protein expression is frequently deregulated in BTC but does not influence clinical prognosis. Their usefulness as prognostic biomarkers in BTC is very limited.

Indexed as

AdultAgedAged, 80 and overBile Duct NeoplasmsBile Ducts, ExtrahepaticBile Ducts, IntrahepaticCholangiocarcinomaFemaleGallbladder NeoplasmsHumansImmunohistochemistryInhibitor of Differentiation Protein 1Inhibitor of Differentiation Protein 2Inhibitor of Differentiation ProteinsKaplan-Meier EstimateMaleID1 protein, humanID2 protein, humanID3 protein, humanID4 protein, humanInhibitor of Differentiation Protein 1Inhibitor of Differentiation Protein 2Inhibitor of Differentiation ProteinsNeoplasm ProteinsBiliary tract cancerCholangiocarcinomaInhibitor of differentiationPrognostic factors

Identifiers

PMID24409060
PMCPMC3882406
OpenAlexW2171945454

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.